Literature DB >> 18288989

Human leukemia and lymphoma cell lines as models and resources.

Roderick A F MacLeod1, Stefan Nagel, Michaela Scherr, Björn Schneider, Wilhelm G Dirks, Cord C Uphoff, Hilmar Quentmeier, Hans G Drexler.   

Abstract

Tumor cell lines are widely used as oncologic models and resources, forming, along with primary patient material and animal models, one of three major subjects for cancer investigation. With the advent of the Human Genome Project (HGP) and the ensuing provision of sequencing data and mapped clones, human cancer cell lines, notably those derived from leukemia-lymphoma (LL) have become increasingly productive tools for cancer gene ascertainment and characterization. Hence, the roles of putative novel cancer genes may be investigated using diverse panels of LL cell lines, both individually by PCR-based methods, and globally by transcriptional chip-profiling. Similar studies have also enabled the faithfulness with which cancer cell lines model their supposed in vivo counterparts to be quantified at last. Several recent transcriptional profiling studies indicate that of all tumor types well characterized human LL cell lines most accurately model the gene expression patterns of their corresponding primary tumors. Analysis using genomic arrays tells a similar story for the stability of chromosome rearrangements in LL cell lines. Well characterized LL cell lines also provide ideal tools for investigating the druggability of individual gene products, e.g. by measuring their transcript levels using q(uantitative)-PCR methods in cells subjected to treatments with small interfering (si)-RNAs. We provide a list of authentic, well characterized examples for prospective investigators, since many circulating cell lines have been cross-contaminated and describe DNA profiling methods which, together with classic and molecular cytogenetic analyses, inform authentication. We also review the problem of mycoplasma contamination and means for its eradication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288989     DOI: 10.2174/092986708783497319

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  13 in total

Review 1.  Dielectrophoresis-based microfluidic platforms for cancer diagnostics.

Authors:  Jun Yuan Chan; Aminuddin Bin Ahmad Kayani; Mohd Anuar Md Ali; Chee Kuang Kok; Burhanuddin Yeop Majlis; Susan Ling Ling Hoe; Marini Marzuki; Alan Soo-Beng Khoo; Kostya Ken Ostrikov; Md Ataur Rahman; Sharath Sriram
Journal:  Biomicrofluidics       Date:  2018-02-23       Impact factor: 2.800

2.  t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.

Authors:  Stefan Ehrentraut; Stefan Nagel; Michaela E Scherr; Björn Schneider; Hilmar Quentmeier; Robert Geffers; Maren Kaufmann; Corinna Meyer; Monika Prochorec-Sobieszek; Rhett P Ketterling; Ryan A Knudson; Andrew L Feldman; Marshall E Kadin; Hans G Drexler; Roderick A F MacLeod
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

3.  Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.

Authors:  Haiping Dai; Stefan Ehrentraut; Stefan Nagel; Sonja Eberth; Claudia Pommerenke; Wilhelm G Dirks; Robert Geffers; Srilaxmi Kalavalapalli; Maren Kaufmann; Corrina Meyer; Silke Faehnrich; Suning Chen; Hans G Drexler; Roderick A F MacLeod
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

4.  Comprehensive genomic characterization of five canine lymphoid tumor cell lines.

Authors:  Sarah C Roode; Daniel Rotroff; Kristy L Richards; Peter Moore; Alison Motsinger-Reif; Yasuhiko Okamura; Takuya Mizuno; Hajime Tsujimoto; Steven E Suter; Matthew Breen
Journal:  BMC Vet Res       Date:  2016-09-17       Impact factor: 2.741

5.  Expansion of functional personalized cells with specific transgene combinations.

Authors:  Christoph Lipps; Franziska Klein; Tom Wahlicht; Virginia Seiffert; Milada Butueva; Jeannette Zauers; Theresa Truschel; Martin Luckner; Mario Köster; Roderick MacLeod; Jörn Pezoldt; Jochen Hühn; Qinggong Yuan; Peter Paul Müller; Henning Kempf; Robert Zweigerdt; Oliver Dittrich-Breiholz; Thomas Pufe; Rainer Beckmann; Wolf Drescher; Jose Riancho; Carolina Sañudo; Thomas Korff; Bertram Opalka; Vera Rebmann; Joachim R Göthert; Paula M Alves; Michael Ott; Roland Schucht; Hansjörg Hauser; Dagmar Wirth; Tobias May
Journal:  Nat Commun       Date:  2018-03-08       Impact factor: 14.919

6.  Establishment and characterization of a novel childhood acute lymphoblastic leukemia cell line, HXEX-ALL1, with chromosome 9p and 17p deletions.

Authors:  Yiping Zhu; Rong Yang; Ju Gao; Yanle Zhang; Ge Zhang; Ling Gu
Journal:  Cancer Cell Int       Date:  2019-04-29       Impact factor: 5.722

7.  The LL-100 panel: 100 cell lines for blood cancer studies.

Authors:  Hilmar Quentmeier; Claudia Pommerenke; Wilhelm G Dirks; Sonja Eberth; Max Koeppel; Roderick A F MacLeod; Stefan Nagel; Klaus Steube; Cord C Uphoff; Hans G Drexler
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

8.  Establishment and characterization of HBV-associated B lymphocytes with an immortalization potential.

Authors:  Xiaoying Qi; Xien Gui; Ke Zhuang
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

9.  Establishment and characterization of HXWMF-1: the first mouse fibroblastic tumor cell line derived from leukemia-associated fibroblasts.

Authors:  Yuanyuan Li; Ling Gu
Journal:  Cancer Cell Int       Date:  2021-03-19       Impact factor: 5.722

10.  A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Authors:  Kelsie L Thu; Mahboubeh Papari-Zareei; Victor Stastny; Kai Song; Michael Peyton; Victor D Martinez; Yu-An Zhang; Isabel B Castro; Marileila Varella-Garcia; Hanquan Liang; Chao Xing; Ralf Kittler; Sara Milchgrub; Diego H Castrillon; Heather L Davidson; C Patrick Reynolds; Wan L Lam; Jayanthi Lea; Adi F Gazdar
Journal:  Oncotarget       Date:  2016-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.